Pathways to Access Summit (Paths): Psychedelic Therapeutics in Europe and Beyond

What Pathways are saying about their ICPR add-on event:

With the FDA likely approving MDMA-assisted therapy as a treatment for PTSD later this year in the United States, and the evidence supporting the potential of psychedelic therapies further accumulating, 2024 is shaping up to be a pivotal year for the therapeutic use of psychedelics. However, the path to approval and - crucially - patient access in Europe remains uncertain. 

The full-day Pathways to Access Summit (Paths) convenes key stakeholders from Europe and beyond to explore the opportunities and challenges around the development, approval, and eventual integration of psychedelic medicines into mainstream European health care.

Find out more using the link below…